DAILIES® AquaComfort Plus® Multifocal (MF) - Comparative Assessment of Visual Performance

June 8, 2016 updated by: Alcon Research

DAILIES® AquaComfort Plus® MF - Comparative Assessment of Visual Performance Using Objective Measurements

The purpose of this study is to evaluate the visual performance of DAILIES® Aqua Comfort Plus® (DACP) MF contact lens using new objective measurements.

Study Overview

Detailed Description

In this 3-treatment, 3-period, 6-sequence crossover study, each subject received all 3 products in randomized order and used 1 product at a time for a duration of 5±1 days before switching to the next assigned product.

Study Type

Interventional

Enrollment (Actual)

24

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

41 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • History of soft contact lens wear (hydrogel or silicone hydrogel) in both eyes during the past 3 months and able to wear lenses at least 8 hours a day, 5 days a week
  • Spectacle add between +1.50 and +2.50 diopters (D) (inclusive)
  • Requiring lenses within the power range of both study contact lenses to be fitted
  • Cylinder, if present, less or equal to 0.50D in both eyes at Visit 1
  • Vision correctable to 20/30 (0.2 logMAR) or better in each eye at distance
  • Acceptable fit with both study contact lenses
  • Willing to wear lenses every day or at least for a minimum of 5 days per week 6 hours per day, every day if possible
  • Other protocol-defined inclusion criteria may apply

Exclusion Criteria:

  • Current multifocal contact lens wearer
  • Current monovision wearer or failed attempt with monovision
  • Ocular anterior segment infection, inflammation, abnormality, or active disease that would contraindicate contact lens wear
  • Use of systemic or ocular medications which contact lens wear could be contraindicated as determined by the investigator
  • Eye injury or surgery within 12 weeks immediately prior to enrollment in this trial
  • Any moderate or severe ocular condition observed during the slitlamp examination at the enrollment visit
  • History of herpetic keratitis, ocular surgery or irregular cornea
  • Prior refractive surgery (e.g. LASIK, PRK, etc)
  • Monocular (only 1 eye with functional vision) or fit with only 1 lens
  • Habitually uncorrected anisometropia >2.00D
  • Clinically significant anisocoria
  • Participation in any clinical trial within 30 days of the enrollment visit
  • Other protocol-defined exclusion criteria may apply

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: DACP MF
DACP MF worn first, followed by DACP and DACP MF (Low Add) as randomized. Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality. DACP MF will be worn bilaterally (in both eyes).
Multifocal contact lenses in Low, Medium, High Add
Active Comparator: DACP
DACP worn first, followed by DACP MF and DACP MF (Low Add), as randomized. Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality. DACP worn as monovision (distance correction in one eye and near correction in the other eye).
Multifocal contact lenses in Low, Medium, High Add
Active Comparator: DACP MF (Low Add)
DACP MF (Low Add) worn first, followed by DACP and DACP MF, as randomized. Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality. DACP MF (Low Add) worn bilaterally (in both eyes).
Multifocal contact lenses in Low, Medium, High Add

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Area for Each Region (Near and Intermediate) Under the Mean Defocus Curve (AUC) at High Luminance
Time Frame: Day 5, each product
Visual acuity was measured with contact lenses in place using an Early Treatment Diabetic Retinopathy Study (ETDRS) high contrast logMAR chart under well-lit conditions. Lenses of different spherical powers (+2.00 diopter to -5.00 diopter) were placed in front of the eyes to produce varying levels of defocus, and logMAR acuity at each defocus value was recorded. The area under the defocus curve (AUC) was calculated via the trapezoidal rule for the entire study population by treatment using a 0.3 logMAR threshold for intermediate from -2.00 D (50cm) to -0.50 D (2m) and near from -4.00 D (25cm) to -2.00 D (50cm). A higher value indicates a bigger area of focus. This outcome measure was prespecified for monovision and DACP MF.
Day 5, each product

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Clinical Manager, EMEA, Alcon Research

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2014

Primary Completion (Actual)

October 1, 2014

Study Completion (Actual)

October 1, 2014

Study Registration Dates

First Submitted

September 8, 2014

First Submitted That Met QC Criteria

September 9, 2014

First Posted (Estimate)

September 10, 2014

Study Record Updates

Last Update Posted (Estimate)

July 11, 2016

Last Update Submitted That Met QC Criteria

June 8, 2016

Last Verified

June 1, 2016

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CLT330-P001

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Refractive Error

Clinical Trials on Nelfilcon A MF contact lenses (DACP MF)

Subscribe